FN1抗体

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Flow cytometric analysis of HeLa cells using FN1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human lung cancer tissues using FN1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human stomach cancer tissues using FN1 mouse mAb with DAB staining.    

  
  

The FN1 antibody targets fibronectin (FN1), a high-molecular-weight glycoprotein critical for cell adhesion, migration, and differentiation. Fibronectin exists in soluble plasma and insoluble cellular forms, both derived from alternative splicing of the FN1 gene. It plays a key role in extracellular matrix (ECM) organization, wound healing, embryogenesis, and maintaining tissue integrity by interacting with integrins, collagen, and other ECM components. FN1 dysregulation is linked to fibrosis, cancer metastasis, and vascular diseases, making it a biomarker in pathological studies.

FN1 antibodies are widely used in research to detect fibronectin localization, expression levels, and structural variants. They aid in studying ECM remodeling in cancer progression, tissue repair, and fibrotic disorders via techniques like Western blot, immunohistochemistry, and immunofluorescence. Monoclonal FN1 antibodies offer high specificity for distinct epitopes or isoforms, while polyclonal versions detect broader epitopes, enhancing sensitivity for fragmented or denatured fibronectin. Validation often involves knockout controls or recombinant protein assays to ensure minimal cross-reactivity. Commercial FN1 antibodies are typically generated using recombinant fragments or purified fibronectin, with applications spanning basic research, diagnostics, and therapeutic development targeting ECM-related pathologies.